Scarica l'app Stockscreener
4.285
2.27%
0.095
Dopo l'orario di chiusura:
4.29
0.005
+0.12%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$4.19
Aprire:
$4.23
Volume 24 ore:
1.89M
Relative Volume:
0.31
Capitalizzazione di mercato:
$848.88M
Reddito:
$191.45M
Utile/perdita netta:
$160.72M
Rapporto P/E:
5.2097
EPS:
0.8225
Flusso di cassa netto:
$-34.44M
1 W Prestazione:
+2.51%
1M Prestazione:
-15.32%
6M Prestazione:
-4.35%
1 anno Prestazione:
-4.14%
Intervallo 1D:
$4.215
$4.30
Intervallo di 1 settimana:
$4.05
$4.30
Portata 52W:
$3.50
$5.45
Arbutus Biopharma Corp Stock (ABUS) Company Profile
Nome
Arbutus Biopharma Corp
Settore
Industria
Telefono
604-419-3200
Indirizzo
701 VETERANS CIRCLE, WARMINSTER, PA
Compare ABUS vs VRTX, MRNA, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABUS
Arbutus Biopharma Corp
|
4.285 | 848.88M | 191.45M | 160.72M | -34.44M | 0.8225 |
VRTX
Vertex Pharmaceuticals Inc
|
508.74 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.35 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.50 | 53.23B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.30 | 42.34B | 5.76B | 514.49M | 1.10B | 4.4813 |
Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-02-02 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-02-25 | Iniziato | Jefferies | Hold |
| 2020-12-17 | Iniziato | H.C. Wainwright | Buy |
| 2020-07-27 | Ripresa | JMP Securities | Mkt Outperform |
| 2020-07-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-05-19 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2020-03-06 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2020-02-20 | Iniziato | Robert W. Baird | Outperform |
| 2020-02-05 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-10-07 | Reiterato | B. Riley FBR | Buy |
| 2019-10-04 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2018-10-16 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2018-10-15 | Aggiornamento | Wedbush | Underperform → Neutral |
| 2018-10-12 | Reiterato | Chardan Capital Markets | Buy |
| 2018-07-06 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-03-19 | Ripresa | Chardan Capital Markets | Buy |
| 2018-03-19 | Downgrade | Wedbush | Outperform → Neutral |
| 2018-01-05 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-04-04 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2017-02-01 | Reiterato | Wedbush | Outperform |
| 2016-12-13 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2016-11-30 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
Mostra tutto
Arbutus Biopharma Corp Borsa (ABUS) Ultime notizie
Form 13D/A Arbutus Biopharma Corp For: 5 October By Investing.com - Investing.com UK
At $5 a share, Arbutus Biopharma (ABUS) accepts tendered shares; Roivant retains about 19.5%. - Stock Titan
The share offer capped at $230M has expired. Arbutus (ABUS) announces final results. - Stock Titan
About 23% of Arbutus shares are being bought back for $230 million. - Stock Titan
Arbutus gains on plans to buy back 46M shares in tender offer - TradingView
Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer - GlobeNewswire
Form 4 Arbutus Biopharma Corp For: 23 September By Investing.com - Investing.com Canada
Q32 Bio (Nasdaq:QTTB)Stock Analysis - simplywall.st
Arbutus Biopharma Stock Price Forecast. Should You Buy ABUS? - StockInvest.us
ABUS Stock Price, Quote & Chart - ChartMill
An 8% holder now reports a passive stake in Arbutus Biopharma (ABUS) - Stock Titan
Arbutus Biopharma Corp (ABUS) Peer Comparison – Compare with Others - Value Research
Arbutus Biopharma (ABUS) Edges Up to $5.12, Stuck Between $4.86 Support and $5.38 ResistanceVolatility Term Structure - careplusvn.com
Arbutus Biopharma Corp (ABUS) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com
Quantum BioPharma Ltd Peer Comparison – Compare with Others - Value Research
Cronos Group Inc. Common Share (CRON) Peer Comparison – Compare with Others - Value Research
Acasti Pharma Inc. Class AADR Peer Comparison – Compare with Others - Value Research
Arbutus Biopharma Corp (ABUS) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Arbutus Biopharma Launches Modified Dutch Auction Tender Offer to Repurchase Up to US$230 Million of Common Shares - Quiver Quantitative
Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share - Yahoo Finance
Arbutus Commences US$230 Million Modified “Dutch - GlobeNewswire
Arbutus Biopharma Launches $230 Million Tender Offer for Common Shares - Yahoo Finance
Arbutus Biopharma Launches Modified Dutch Auction Tender Offer to Repurchase Up to US$230 Million of Common Shares - Quiver Quantitative
Arbutus Biopharma (NASDAQ:ABUS) Capital Strategy Draws Attention - Kalkine Media
Why Is Arbutus Biopharma Stock Gaining Friday? - TradingView
ABUS Stock Pops As Moderna Settlement Transforms Balance Sheet - StocksToTrade
Arbutus Biopharma Announces $230 Million Modified Dutch Auction Tender Offer for Shares - Kalkine Media
Why is Arbutus Biopharma stock surging today? - Investing.com India
Why is Arbutus Biopharma stock surging today? - Investing.com
Why is Arbutus Biopharma stock surging today? By Investing.com - Investing.com UK
Arbutus Biopharma shares jump after unveiling $230 million share buyback plan - Yahoo Finance
ABUS Stock Surges 10% Today — What’s Driving This Super Rally? - Stocktwits
ABUS Stock Surges 10% Today — What’s Driving This Super Rally? - Yahoo Finance
ABUS Looks 90.4% Undervalued on GF Value™ Despite Possible Value Trap - GuruFocus
Arbutus Biopharma stock surges on $230M buyback plan - Investing.com
Arbutus (NASDAQ: ABUS) plans Dutch auction share buyback - Stock Titan
ABUS Looks 90.4% Undervalued on GF Value™ - GuruFocus
Arbutus Biopharma Announces Plans for Up to $230 Million Modified Dutch Auction Tender Offer - Quiver Quantitative
Arbutus Announces Intent to Repurchase Up to US$230 Million - GlobeNewswire
Arbutus Biopharma Corporation announces an Equity Buyback for $230 million worth of its shares. - marketscreener.com
Arbutus Gains on $230m Buyback Using Moderna Settlement Proceeds - Bloomberg.com
ABUS Stock Surges 10% Today — What’s Driving This Super Rally? - TradingView
Moderna, Arbutus Clash On Gov't Venue For Vax IP Claims - Law360
Arbutus Plans $230 Million Share Buyback After Moderna Deal - MyChesCo
Arbutus Biopharma (NASDAQ:ABUS) Cut to Hold at Wall Street Zen - MarketBeat
ABUS|Arbutus Biopharma Corp|Price:4.710|Chg%:+0.130 - TradingKey
Arbutus Biopharma (ABUS) Stock Profit Surge Leaves Durability Questions Open - simplywall.st
Morgan Stanley (ABUS) units report near-9% Arbutus Biopharma stake in 13G/A filing - stocktitan.net
Arbutus Biopharma earnings matched, revenue topped estimates By Investing.com - Investing.com Nigeria
Arbutus Biopharma (NASDAQ:ABUS) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Arbutus Biopharma Corp Azioni (ABUS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Arbutus Biopharma Corp Azioni (ABUS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Nguyen Tuan | Chief Financial Officer |
Sep 18 '26 |
Option Exercise |
3.57 |
293,100 |
1,047,646 |
366,600 |
| Sawhney Roger | Director |
Sep 18 '26 |
Option Exercise |
3.88 |
131,333 |
509,572 |
131,333 |
| Beardsley Robert A | Director |
Sep 18 '26 |
Option Exercise |
3.82 |
131,333 |
502,218 |
131,333 |
2.35%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):